- Home
- BOLD vs CVKD Comparison
BOLD vs CVKD Comparison
Compare BOLD & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- CVKD
- Stock Information
- Founded
- BOLD 2018
- CVKD 2022
- Country
- BOLD United States
- CVKD United States
- Employees
- BOLD N/A
- CVKD N/A
- Industry
- BOLD
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BOLD
- CVKD Health Care
- Exchange
- BOLD Nasdaq
- CVKD Nasdaq
- Market Cap
- BOLD 30.3M
- CVKD 29.5M
- IPO Year
- BOLD 2024
- CVKD 2023
- Fundamental
- Price
- BOLD $1.07
- CVKD $12.80
- Analyst Decision
- BOLD Buy
- CVKD Strong Buy
- Analyst Count
- BOLD 3
- CVKD 1
- Target Price
- BOLD $4.00
- CVKD $32.00
- AVG Volume (30 Days)
- BOLD 363.5K
- CVKD 32.3K
- Earning Date
- BOLD 08-11-2025
- CVKD 08-06-2025
- Dividend Yield
- BOLD N/A
- CVKD N/A
- EPS Growth
- BOLD N/A
- CVKD N/A
- EPS
- BOLD N/A
- CVKD N/A
- Revenue
- BOLD N/A
- CVKD N/A
- Revenue This Year
- BOLD N/A
- CVKD N/A
- Revenue Next Year
- BOLD N/A
- CVKD N/A
- P/E Ratio
- BOLD N/A
- CVKD N/A
- Revenue Growth
- BOLD N/A
- CVKD N/A
- 52 Week Low
- BOLD $1.00
- CVKD $5.70
- 52 Week High
- BOLD $4.72
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- CVKD 49.60
- Support Level
- BOLD N/A
- CVKD $11.00
- Resistance Level
- BOLD N/A
- CVKD $13.71
- Average True Range (ATR)
- BOLD 0.00
- CVKD 1.14
- MACD
- BOLD 0.00
- CVKD 0.10
- Stochastic Oscillator
- BOLD 0.00
- CVKD 63.54
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.